Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Malmo – page 66

1 356 clinical trials in Malmo, Sweden across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Malmo at a glance
1 356
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

1 356 trials in Malmo

Open in trial search

Cardiac amyloidosis

Not recruiting

Efficacy and safety of eplontersen sodium plus ALXN2220 in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Not recruiting

Continuation study of JDQ443 in patients with KRAS G12C‑mutated non‑small cell lung cancer receiving JDQ443 as monotherapy or drug combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Novartis Pharma AG

Chronic rhinosinusitis with nasal polyps

Not recruiting

Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Infertility male

Not recruiting

A study to evaluate the use of leflutrozole to improve semen quality in men with non-obstructive azoospermia

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · Healthy volunteers
  • Substances:Leflutrozole
  • Sponsor:Region Hovedstaden

Small cell lung cancer extensive stage

Not recruiting

Study of tarlatamab and durvalumab compared to durvalumab alone for patients with extensive stage small cell lung cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Amgen Inc.

Herpes zoster

Not recruiting

Evaluating the effect of recombinant varicella zoster virus glycoprotein E vaccine on heart problems and dementia in adults aged 65 years or older with herpes zoster

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years · Healthy volunteers
  • Sponsor:Gentofte Hospital

Cervix carcinoma+1

Not recruiting

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

Diffuse large B-cell lymphoma refractory

Not recruiting

A study evaluating glofitamab and a drug combination for patients with relapsed or refractory diffuse large B-cell lymphoma.

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:F. Hoffmann-La Roche AG

Osteosarcoma

Not recruiting

Efficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Cabozantinib
  • Sponsor:Ipsen Innovation

Prostate cancer

Not recruiting

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Amgen Inc.

Squamous cell carcinoma of head and neck

Not recruiting

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:BioNTech SE

Ovarian cancer

Not recruiting

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tuvusertib
  • Sponsor:Merck Healthcare KGaA

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Malmo

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on metastatic prostate cancer treatments and breakthrough therapies for colorectal cancer. Research includes studies of novel drug combinations and targeted therapies for breast cancer patients.

  • Advanced prostate cancer treatments
  • Colorectal cancer interventions
  • Breast cancer therapy optimization
02 Neurodegenerative Disorders

Comprehensive studies on Alzheimer's disease diagnostics and treatment, including innovative research on ALS therapies. Investigations utilize advanced imaging techniques and novel therapeutic approaches.

  • Early Alzheimer's intervention
  • ALS treatment development
  • Cognitive disorder diagnostics
03 Metabolic and Chronic Conditions

Trials examining treatments for obesity and type 2 diabetes, along with innovative approaches to managing chronic kidney disease. Research focuses on biomarker-targeted treatments and lifestyle interventions.

  • Weight management therapies
  • Diabetes treatment optimization
  • Kidney disease interventions
04 Infectious Diseases

Studies evaluating vaccines for respiratory syncytial virus, HPV, and Herpes Zoster. Research aims to prevent viral infections and improve vaccination strategies in various age groups.

  • Viral infection prevention
  • Vaccine effectiveness studies
  • Immunization programs
Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.